J

Johnson & Johnson

Makes prescription drugs and medical devices

Vision CQ Transportation Quality Specialist - APAC & Japan

Full-TimePosted on 10/16/2026Deadline 10/26/26
No salary listed
Senior
Bachelor's
Mumbai, Maharashtra, India+1 moreMore locations: Shanghai, China
HybridSupports stakeholders across APAC and Japan time zones; travel of approximately 15–25% may be required.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree is required.
  • At least five years of experience in a regulated healthcare industry, including medical devices, pharmaceuticals, and/or diagnostics, with quality, regulatory compliance, distribution, supplier quality coordination, transportation, or supply chain quality experience.
  • Experience supporting transportation quality operations, investigations, CAPAs, quality events, change controls, metrics reporting, trend analysis, and cross-functional project activities.
  • Knowledge of applicable global regulations and experience collaborating with professionals in a matrixed environment.
  • Working knowledge of transportation quality management, Good Distribution Practices, quality management systems, supplier quality coordination, carrier performance, qualification activities, issue escalation, and compliant logistics operations.
  • Knowledge of lane and route qualification, lane mapping, temperature-controlled transportation, temperature excursion management, transportation risk assessment, and logistics-provider oversight.
  • Ability to partner with Transportation Operations, Supply Chain, Procurement, APAC and Japan regional Commercial Quality teams, and external suppliers in a matrixed environment.
  • Analytical and problem-solving ability, including using metrics, scorecards, and trends to identify risk and drive action.
  • Ability to communicate, collaborate, influence, and present effectively across Quality and Compliance, Supply Chain, Commercial, and external partner organizations.
  • Ability to manage multiple priorities, clarify complex topics, and operate across strategic, tactical, high-level, and detailed perspectives in an ambiguous environment.
  • Ability to prepare clear, accurate, decision-ready Vision-specific data for governance review and collaborate with MedTech and Innovative Medicine colleagues on occasional cross-segment transportation investigations.
  • Fluent English and Japanese language capability, including communicating with Japan-based stakeholders and supporting the review or coordination of Japan-related transportation quality documentation.
  • Ability to support stakeholders across APAC and Japan time zones.
  • Travel of approximately 15–25% may be required, depending on business needs.
Responsibilities
  • Provide operational quality oversight for inter-regional transportation activities impacting APAC and Japan, partnering with regional Commercial Quality, Transportation Operations, Supply Chain, Procurement, carriers, control towers, and logistics providers.
  • Lead or support transportation-related investigations, nonconformances, CAPAs, deviations, change controls, complaints, product-impact assessments, effectiveness checks, and associated quality records through timely closure.
  • Assess and coordinate resolution of transportation incidents, temperature excursions, damage, contamination, losses, mis-deliveries, seal issues, and service failures; escalate material risks in accordance with established processes.
  • Support transportation supplier quality activities, including carrier qualification, quality agreements, supplier audits, performance reviews, corrective-action follow-up, and remediation.
  • Support transportation lane and route qualification, lane mapping, shipping-route verification, transportation risk assessments, temperature-control qualification, and network changes.
  • Provide quality support for new product introductions, transfers, business-continuity activities, and projects that change transportation routes, providers, systems, or operating processes.
  • Build, maintain, and report transportation quality metrics, dashboards, scorecards, and trend analyses; identify emerging risks, recurring issues, and improvement opportunities.
  • Maintain complete, accurate, and retrievable documentation and evidence packages to support internal audits, supplier audits, health authority inspections, and notified-body assessments.
  • Contribute to process simplification, harmonization, training, communications, and capability-building initiatives as transportation responsibilities transition into Vision CQ.
  • Prepare and validate Vision-specific transportation quality data, metrics, trend analyses, risks, and investigation insights for governance meetings and management reviews.
  • Provide Vision-specific supporting information and subject-matter input in response to governance requests, ensuring that Vision transportation issues, trends, and regulatory considerations are accurately represented.
  • Work with MedTech and Innovative Medicine quality colleagues on occasional cross-segment transportation investigations, contributing Vision-specific evidence, product and lane impact assessments, root-cause input, and agreed follow-up activities.
  • Provide technical quality guidance, support workflow execution, and contribute to departmental transportation quality priorities.
Desired Qualifications
  • A degree concentration in Life Science, Engineering, Technical Business, Quality, Regulatory Compliance, Supply Chain, Logistics, or a related discipline.
  • Experience supporting transportation qualification, supplier quality activities, new product introductions, network changes, remediation, and/or quality improvement activities.
  • Experience preparing operational quality data, metrics, trends, and risk information for governance or management review, and collaborating across functions on shared investigations or issue resolution.
  • Previous experience supporting audits or interfacing with regulatory agencies and notified bodies.
  • Quality auditing, GDP, project management, supply chain, logistics, Lean, or Six Sigma certification is desirable.
  • Audit Management, Business Savvy, Coaching, Communication, Compliance Management, Continuous Improvement, Fact-Based Decision Making, ISO 9001, Issue Escalation, Problem Solving, Quality Control (QC), Quality Management Systems (QMS), Quality Standards, Regulatory Environment, and Standard Operating Procedure (SOP).

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.